Shares of The Cigna Group (NYSE: CI) have gained 25.6% in the past year compared with the industry's 18.2% growth. The Medical sector and the S&P 500 composite index have rallied 9.3% and 21.2%, respectively, in the same time frame. CI has been well-poised for growth on the back of a sound membership base, solid Evernorth unit, acquisitions and expanding cash reserves.
Currently priced at $357.40, the stock is just 3.6% below its 52-week high of $370.64. This proximity underscores investor confidence and market optimism about Cigna's prospects.
The health insurer, presently carrying a Zacks Rank #3 (Hold), has an impressive record of beating estimates in each of the trailing four quarters, the average surprise being 3.83%.
Image Source: Zacks Investment Research
Robust Growth Prospects of CI Stock
The Zacks Consensus Estimate for Cigna's 2024 earnings is pegged at $28.48 per share, which indicates a 13.5% increase from the 2023 figure. The consensus mark for revenues is $239.1 billion, which implies 22.4% growth from the year-ago figure.
The Zacks Consensus Estimate for 2025 earnings is pegged at $31.80 per share, which implies an 11.7% improvement from the 2024 estimate. The consensus mark for revenues is $246.5 billion, implying a 3.1% rise from the 2024 estimate.
Cigna's Business Tailwinds
Cigna's performance is underscored ...
